The company's principal activity is to develop biopharmaceutical drugs used for the treatment of autoimmune and inflammatory diseases. The bioregulatory compounds are based on the principle of normalizing the activities of immune cells at a more basic level than traditional pharmaceutical agents, which act upon the end products of complex metabolic pathways. The company is in its development stage and currently has no products in the market.
